Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...
For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is noninferior to guideline-concordant care (GCC) ...
Medpage Today on MSN4d
Case Study: Treating Malignant Breast Cancer in a Resource-Limited AreaA noteworthy case study. What's next for a premenopausal 40-year-old woman in Syria with recurrent hormone receptor-positive ...
Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...
Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.
Researchers reveal new insights on the growth of craniopharyngioma and identified a potential therapeutic treatment.
New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...
Chinese researchers have revealed new insights into the growth of craniopharyngioma and identified a potential therapeutic ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...
The model uses clinical and genomic features to predict whether patients will respond to first-line CDK4/6 and endocrine therapy.
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback